Construction and Application of Four-Dimensional and Chained Research Platform for Pharmacovigilance of Traditional Chinese Medicine

doi:10.19803/j.1672-8629.2021.05.04

Abstract

Abstract: Objective To construct a four-dimensional and chained research platform for pharmacovigilance of TCM given the complexity of safe clinical use of traditional Chinese medicine (TCM) in order to provide reference and guidance for research on the safety of TCM. Methods By exploring the critical elements of pharmacovigilance of TCM, the core models of risk signal discovery, risk evidence enhancement, risk-benefit assessment and drug risk communication were utilized by the platform, which could comprehensively, systematically, quantitatively and accurately discover, determine, assess and prevent problems with safety of clinical medication of TCM. Results This research platform was not only able to integrate the models of risk signal mining, risk evidence enhancement, risk benefit evaluation and drug risk communication, but used for pharmacovigilance research of TCM. Conclusion The four-dimensional and chained research platform of TCM pharmacovigilance can be used to comprehensively and Objectively account for the complex problems with the safety of TCM, properly and systematically clarify the essence of traditional ideas about safe application of TCM, and promote the implementation and development of TCM pharmacovigilance.

Key words: traditional Chinese medicine (TCM), pharmacovigilance, four-dimensional and chained, research platform, research model

CLC Number:

R28R944.11

ZHANG Dan, LYU Jintao, ZHANG Bing, LIN Zhijian, WU Huanzhang, ZHANG Xiaomeng. Construction and Application of Four-Dimensional and Chained Research Platform for Pharmacovigilance of Traditional Chinese Medicine[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 416-421.

References

[1] Sarker A,Ginn R,Nikfarjam A,et al.Utilizing social media data for pharmacovigilance:A review[J].J Biomed Inform,2015,54:202-212.
[2] Law of the PRC Governing the Management of Pharmaceutical Products[EB/OL].(2019-08-26)[2020-11-05].http://www.gov.cn/xinwen/2019-08/26/content_5424780.htm.
[3] Wu JR,Zhang B.Discussion of traditional chinese medicine pharmacovigilance[J].Chinese Journal of Pharmacoepidemiology(药物流行病学杂志),2009,18(5):312-315.
[4] Zhang B,Lin ZJ,Zhang XM,et al.Pharmacovigilance of chinese medicine:mining and practice[J].Chinese Journal of Pharmacoe-pidemiology(药物流行病学杂志),2016,25(7):405-408.
[5] NMPA Implementation opinions of the state food and drug administration on promoting the inheritance and innovation of traditional chinese medicine[EB/OL].(2020-12-25)[2021-01-05].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20201225163906151.html?type=pc&m=&from=timeline&isappinstalled=0&GXMEUwefOdZn=1608980146597.
[6] Gao Y,An H,Xu WH,et al.Discussion on pharmacovigilance of traditional chinese medicine[J].Journal of Basic Chinese Medicine(中国中医基础医学杂志),2019,25(2):233-234.
[7] NMPA The State Drug Administration.Pharmacovigilance quality management standard (Exposure Draft)[EB/OL].(2020-12-03)[2021-01-05].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20201203164737146.html?type=pc&m=&GXMEUwefOdZn=1608987716806.
[8] Zhang B.Pharmacovigilance of Chinese medicine (中药药物警戒)[M].Beijing:People's Medical Publishing House,2015:3-4.
[9] Wang Y,Zhang B,Lin ZJ,et al.Chinese materia medica for suppressing hyperactive liver and calming endogenous wind:Safety analysis and pharmacovigilance considerations[J].China Journal of Traditional Chinese Medicine and 0harmacy(中华中医药杂志),2016,31(11):4643-4648.
[10] Bai YF,Lin ZJ,Zhang B,et al.Chinese materia medica for rheum-atism:Safety analysis and pharmacovigilance considerations[J].China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志),2016,31(10):4117-4123.
[11] Zhao W,Yang W,Gong Y,et al.Analysis of rational use of oral Chinese patent medicines with toxic herbal pieces as main drugs[J].Beijing Jour-nal of Traditional Chinese Medicine(北京中医药),2020,39(3):290-294.
[12] Han L,Sun ZY,Yang W,et al.Safety evaluation and supervision of traditional chinese medicine[J].Chinese Journal of Pharmacology and toxicology(中国药理学与毒理学杂志),2020(11):801-810.
[13] Mao QY,Lin ZJ,Wang Y,et al.Early warning of risks of sennae folium to constipation patients with breast cancer by bioinfo-rmatics[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2021,18(1):30-37.
[14] Zhang D,Dong YZ,Lv JT,et al.Prediction of toxicity mechanism of kunming shanhaitang based on network pharmacology and with molecular docking[J].Journal of Beijing University of Traditional Chinese Medicine(北京中医药大学学报),2019,42(12):1006-1015.
[15] Wang YG,Jin R,Kong XW,et al.Safety grade of application of traditional chinese medicines during pregnancy[J].Journal of Chinese Materia Medica(中国中药杂志),2016,41(1):150-153.
[16] Zhao YP,Gao R,Lu F,et al.Thoughts on the construction of risk assessment system for the benefits of post-marketed traditional Chinese medicine[J].Beijing Journal of Traditional Chinese Medicine(北京中医药),2013,32(11):803-806.
[17] Dang HX,Zhang L,Liu J,et al.Introduction and analysis of FDA's benefit-risk drug value assessment framework[J].Drug Evaluation Research(药物评价研究),2020,43(4):665-669.
[18] Jin R,Wang YG,Zhang B.Establishment and verification of risk asses-sment scale for clinical safety medication of aconitine[J].China Journal of Chinese Materia Medica(中国中药杂志),2018,43(2):222-226.
[19] Zhang XM,Li F,Zhang B,et al.Data-mining characteristics of adverse drug reactions and pharmacovigilance of chinese patent drugs including aconitum herbs[J].China Journal of Chinese Materia Medica(中国中药杂志),2018,43(2):216-221.
[20] Zhang XM,Lin ZJ,Zhang B,et al.Traditional prescription rules of aconitum herbs in treatment of bi syndrome[J].China Journal of Chinese Materia Medica(中国中药杂志),2018,43(2):211-215.
[21] Li LZ,Chai YF,Xue CM,et al.Effects of fuzi rougui and xianmao on immune function and energy metabolism of rats in different state[J/OL].Chinese 22 Archives of Traditional Chinese Medicine (中华中医药学刊).(2020-11-05)[2021-02-14].http://kns.cnki.net/kcms/detail/21.1546.R.20201104.1844.026.html.
[22] Zhang D,Zhang XM,Dong YZ,et al.A network meta-analysis of aconitum species chinese patent medicines for patients with arthromyodynia[J].Chinese Journal of Pharmacoepidemiology(药物流行病学杂志),2020,29(3):149-157.
[23] Tian ZP,Zhang B,Zhang XM,et al.Application of aconitum medicines in puji fang for children[J].Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志),2019,25(21):176-181.
[24] Wang Y,Lin ZJ,Jiang ZX,et al.Study of early warning of aconitum herbs in breast cancer therapy by bibliometric and bioinformatics[J/OL].Chinese Journal of Pharmacovigilance (中国药物警戒).(2020-12-28)[2021-02-14].http://kns.cnki.net/kcms/detail/11.5219.R.20201228.1325.006.html.
[25] Cui YY,Wu JR,Zhang D,et al.Study on the epidemiological characteristics of adverse reaction caused by heat-clearing injection based on data mining[J].Chinese Journal of Pharmacoepidemiology(药物流行病学杂志),2017,26(10):675-682.
[26] Cui YY,Liu S,Wu JR,et al.Studies on the epidemiological char-acteristics of adverse reaction caused by shuanghuanglian injection bas-ed on bayesian network and decision tree algorithm[J].Chinese Journal of Pharmacoepidemiology(药物流行病学杂志),2017,26(1):19-26.
[27] Lv JT,Zhang B,Lin ZJ,et al.Domestic research progress on the combination of chinese and western medicine based on literature metrology and knowledge graph[J].Chinese Journal of Hospital Pharmacy(中国医院药学杂志),2020,40(21):2269-2275.
[28] Qu CC,Zhang B,Lin ZJ,et al.Pharmacovigilance in materia medica works of qing dynasty[J].Journal of Chinese Materia Medica(中国中药杂志),2019,44(21):4751-4755.
[29] Shi L,Liu X,Zhang B.Study on use of drug toxicity in pharmacovigi-lance thought of the compendium of materia medical[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(7):399-403.
[30] Li F,Dong YZ,Zhang D,et al.Molecular mechanisms involved in drug-induced liver injury caused by urate-lowering chinese herbs:a network pharmacology study and biology experiments[J].PLos One,2019,14(5):e0216948.
[31] Jiang H,Zhang XM,Zhang B,et al.Benefit and risk of tripterygium glycosides tablets in treatment of rheumatoid arthritis based on multi-criteria decision-making analysis[J].Journal of Chinese Materia Medica(中国中药杂志),2020,45(4):798-808.
[32] Tian ZP,Zhang B,Li F,et al.Investigation of clinical medication monitoring in 820 grassroots medical institutions[J].China Pharm- acist(中国药师),2019,22(3):457-461.
[33] Li A,Zhang B.Survey and consideration on safety status of traditional chinese medicine application in 685 primary healthcare workers[J].Chin-ese Journal of Pharmacovigilance(中国药物警戒),2018,15(12):721-727.
[34] Wang Y,Lin ZJ,Dong YZ,et al.Investigation of pharmaceutical services for traditional chinese medication precautions in medical institutions[J].China Pharmacist(中国药师),2018,21(12):2133-2139.